Alopecia Therapeutics – Pipeline Insights 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
ALOPECIA THERAPEUTICS PIPELINE ANALYSIS
• Alopecia is an auto-immune disease of the skin that causes the loss of hair on the face, scalp and less frequently on other parts of the body that can be psychologically devastating.
• The condition can occur in both male and female and at any age. There is five major type of alopecia namely; alopecia areata, androgenic alopecia, cicatricial alopecia, traction alopecia, and alopecia totalis.
• As furnished by National Alopecia Areata Foundation, about 147 million people globally are affected by the disease and approximately 2.1% people have a lifetime risk of developing the disease. Treatment options include steroid injections, topical creams, gels. Immunotherapy is also an available option in some cases.
• Apart from being a genetic disease, alopecia is sometimes seen in patients with a family history of diabetes and rheumatoid arthritis. Also, can be resulted from chemotherapy, immunotherapy, and radiotherapy employed during cancer treatment.
• Increasing prevalence of alopecia is expected to actuate demand for its treatment drugs. Frequent launch, approvals, and robust pipeline along with increased awareness of alopecia treatment products are expected to drive the market growth in the near future.
• However, the presence of an alternative treatment option for alopecia is expected to be a major factor restraining the global alopecia treatment market growth.
• For example, methods such as hair transplant surgery, laser, and light-based therapies are expected to curb the growth of the market. The high cost of medications and possible side effects or allergic reactions act as a barrier for the growth.
• In spite of these, market growth is expected to increase by the advancements in technologies for developing gene therapies.
• The global alopecia treatment market size has grown substantially at a healthy CAGR (about 5%) due to changing lifestyle and greater emphasis on outward appearance to look good. The robust pipeline of Alopecia includes various molecules like OliPass is developing oligonucleotide therapeutics for alopecia which is in the preclinical stage.
• Hair Stimulating Complex of Histogen is in early clinical phase, PF-06651600 of Pfizer is in Phase 2 stage of development, about 29% of the active trials are in phase 2 stage of development as registered in clinicaltrials.gov. Some of the key products available in the market include Baricitinib of Eli Lilly, Propecia of Merck.
• Alopecia is an auto-immune disease of the skin that causes the loss of hair on the face, scalp and less frequently on other parts of the body that can be psychologically devastating.
• The condition can occur in both male and female and at any age. There is five major type of alopecia namely; alopecia areata, androgenic alopecia, cicatricial alopecia, traction alopecia, and alopecia totalis.
• As furnished by National Alopecia Areata Foundation, about 147 million people globally are affected by the disease and approximately 2.1% people have a lifetime risk of developing the disease. Treatment options include steroid injections, topical creams, gels. Immunotherapy is also an available option in some cases.
• Apart from being a genetic disease, alopecia is sometimes seen in patients with a family history of diabetes and rheumatoid arthritis. Also, can be resulted from chemotherapy, immunotherapy, and radiotherapy employed during cancer treatment.
• Increasing prevalence of alopecia is expected to actuate demand for its treatment drugs. Frequent launch, approvals, and robust pipeline along with increased awareness of alopecia treatment products are expected to drive the market growth in the near future.
• However, the presence of an alternative treatment option for alopecia is expected to be a major factor restraining the global alopecia treatment market growth.
• For example, methods such as hair transplant surgery, laser, and light-based therapies are expected to curb the growth of the market. The high cost of medications and possible side effects or allergic reactions act as a barrier for the growth.
• In spite of these, market growth is expected to increase by the advancements in technologies for developing gene therapies.
• The global alopecia treatment market size has grown substantially at a healthy CAGR (about 5%) due to changing lifestyle and greater emphasis on outward appearance to look good. The robust pipeline of Alopecia includes various molecules like OliPass is developing oligonucleotide therapeutics for alopecia which is in the preclinical stage.
• Hair Stimulating Complex of Histogen is in early clinical phase, PF-06651600 of Pfizer is in Phase 2 stage of development, about 29% of the active trials are in phase 2 stage of development as registered in clinicaltrials.gov. Some of the key products available in the market include Baricitinib of Eli Lilly, Propecia of Merck.
